TY - JOUR
T1 - Positron emission tomography in schizophrenia
T2 - a new perspective
AU - Patel, Neva H.
AU - Vyas, Nora S.
AU - Puri, Basant K.
AU - Nijran, Kuldip S.
AU - Al-Nahhas, Adil
PY - 2010/4
Y1 - 2010/4
N2 - PET is an important functional imaging technique that can be used to investigate neurotransmitter receptors and transporters directly by mapping human brain function. PET is increasingly being used greatly to advance our understanding of the neurobiology and pathophysiology of schizophrenia.
METHODS:
This review focuses on the use of PET tracers and kinetic modeling in identifying regional brain abnormalities and regions associated with cognitive functioning in schizophrenia. A variety of PET tracers have been used to identify brain abnormalities, including (11)C, (15)O-water, (18)F-fallypride, and L-3,4-dihydroxy-6-(18)F-fluorophenylalanine ((18)F-FDOPA).
RESULTS:
Some studies have used compartmental modeling to determine tracer binding kinetics. The most consistent findings show a difference in the dopamine content in the prefrontal cortex, anterior cingulate gyrus, and hippocampus between healthy controls and patients with schizophrenia. Studies also show a higher density of D(2) receptors in the striatum and neural brain dysconnectivity.
CONCLUSION:
Future investigations integrating clinical, imaging, genetic, and cognitive aspects are warranted to gain a better understanding of the pathophysiology of this disorder.
AB - PET is an important functional imaging technique that can be used to investigate neurotransmitter receptors and transporters directly by mapping human brain function. PET is increasingly being used greatly to advance our understanding of the neurobiology and pathophysiology of schizophrenia.
METHODS:
This review focuses on the use of PET tracers and kinetic modeling in identifying regional brain abnormalities and regions associated with cognitive functioning in schizophrenia. A variety of PET tracers have been used to identify brain abnormalities, including (11)C, (15)O-water, (18)F-fallypride, and L-3,4-dihydroxy-6-(18)F-fluorophenylalanine ((18)F-FDOPA).
RESULTS:
Some studies have used compartmental modeling to determine tracer binding kinetics. The most consistent findings show a difference in the dopamine content in the prefrontal cortex, anterior cingulate gyrus, and hippocampus between healthy controls and patients with schizophrenia. Studies also show a higher density of D(2) receptors in the striatum and neural brain dysconnectivity.
CONCLUSION:
Future investigations integrating clinical, imaging, genetic, and cognitive aspects are warranted to gain a better understanding of the pathophysiology of this disorder.
KW - Physics
UR - http://www.ncbi.nlm.nih.gov/pubmed/20237027
U2 - 10.2967/jnumed.109.066076
DO - 10.2967/jnumed.109.066076
M3 - Article
C2 - 20237027
SN - 0161-5505
VL - 51
SP - 511
EP - 520
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 4
ER -